A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis
Journal of the European Academy of Dermatology and Venereology · 2026-07-28
DOI: 10.1111/jdv.70643 ↗At a glance
Journal article in Journal of the European Academy of Dermatology and Venereology, published online on 2026-07-28. Written by Ling Han and 24 co-authors. Institution: Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Changzhou Hengbang Pharmaceutical Co., Ltd..
Abstract (original language)
Background
Tyrosine kinase 2 (TYK2), a key part of the inflammatory cascade responses, plays an integral role in the pathogenesis of psoriasis. Socrodeucitinib, an oral, TYK2 allosteric inhibitor, selectively inhibits TYK2 cytokine signalling pathways in psoriasis pathogenesis.
Objectives
To evaluate the efficacy and safety of socrodeucitinib in patients with moderate‐to‐severe plaque psoriasis.
Methods
In this phase 2, double‐blind, placebo‐controlled trial, 125 patients were randomly assigned (1:1:1) to receive socrodeucitinib at 6 mg, 12 mg or placebo orally, once daily, for 12 weeks. The primary endpoint was the proportion of patients with a 75% or greater reduction from the baseline in the Psoriasis Area and Severity Index (PASI) score at week 12.
Results
At week 12, significantly more patients treated with socrodeucitinib achieved a 75% reduction from baseline in PASI score compared with placebo (28.6% at 6 mg, 72.1% at 12 mg vs. 7.5% for placebo, p < 0.05 and p < 0.001, respectively). At the 12 mg dose, socrodeucitinib resulted in significantly higher response rates compared to placebo, with 46.5% of patients achieving PASI 90 ( p < 0.001) and 11.6% achieving PASI 100 ( p < 0.05). The treatment of socrodeucitinib also led to significantly higher proportions of patients achieving sPGA responses of 0 or 1 compared to placebo: 33.3% at 6 mg and 65.1% at 12 mg versus 10% for placebo ( p < 0.05 and p < 0.001, respectively). Most common adverse events included upper respiratory tract infection which demonstrated a certain dose dependency. Most treatment‐related adverse events were mild or moderate, and serious adverse events were infrequent, with no clinically meaningful abnormal trend in laboratory parameters.
Conclusions
Socrodeucitinib demonstrated significantly greater clearing of psoriasis plaques compared to placebo in patients with moderate‐to‐severe plaque psoriasis and illustrated a favourable safety and tolerability profile, warranting further investigation in longer‐duration and larger trials.
Subjects
Author keywords
Authors and institutions
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, China.
- Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
- Department of Dermatology, Northeast International Hospital, Shenyang, China.
- Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China.
- Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, China.
ORCID profiles: Yan Zhou
Funding
- Changzhou Hengbang Pharmaceutical Co., Ltd.
Cite
APA
Han, L., Geng, S., Ding, Y., Zhang, S., Wang, X., Hu, F., Li, J., Ci, C., Hu, Y., Chen, R., Zhang, J., Zhou, X., Chen, A., Zhang, C., Lei, T., Feng, Y., Wang, Y., Meng, Z., Zhou, Y., …, & Xu, J. (2026). A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70643
Vancouver
Han L, Geng S, Ding Y, Zhang S, Wang X, Hu F, et al. A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70643
BibTeX
@article{Han2026,
author = {Han, Ling and Geng, Songmei and Ding, Yangfeng and Zhang, Shifa and Wang, Xiaohua and Hu, Fengming and Li, Jianguo and Ci, Chao and Hu, Yayu and Chen, Rixin and Zhang, Jianping and Zhou, Xiaoyong and Chen, Aijun and Zhang, Chunlei and Lei, Tiechi and Feng, Yanyan and Wang, Yu and Meng, Zudong and Zhou, Yan and Ji, Mingkai and Liu, Wei and Wu, Yunting and Chen, Qianying and Wang, Siyi and Xu, Jinhua},
title = {A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
doi = {10.1111/jdv.70643}
}
EUVIMED